首页 News 正文

On August 13th, the official website of the Drug Evaluation Center (CDE) of the China National Medical Products Administration (NMPA) announced that the Class 1 therapeutic biological product Mataximab Injection, declared by Pfizer, has been approved for listing in China. Marstacimab is a novel hemophilia treatment drug developed by Pfizer, which only requires subcutaneous injection once a week.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

楚一帆 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    38